Clinical Trial Update: Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study in healthy volunteers to assess whether CP-690,550 (tofacitinib) affects metformin exposure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tofacitinib (tofacitinib)
• metformin (metformin)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED